Table 2.
Relationship Between Expression Level of Hsa_Circ_0104824 in Breast Cancer Tissues and Clinicopathological Features of Breast Cancer Patients.
| Parameter | N | Hsa_circ_0104824 level (Mean ± SD) | T-test or One way ANOVA(F) | P |
|---|---|---|---|---|
| Age status | −0.078 | 0.939 | ||
| ≥50 | 21 | 8.65 ± 2.27 | ||
| <50 | 16 | 8.71 ± 2.03 | ||
| CA15-3 status | −5.541 | <0.001** | ||
| CA15-3 positive | 5 | 6.54 ± 0.55 | ||
| CA15-3 negative | 32 | 9.01 ± 2.10 | ||
| CEA status | −0.097 | 0.938 | ||
| CEA positive | 2 | 8.38 ± 4.57 | ||
| CEA negative | 35 | 8.69 ± 2.05 | ||
| Tumor size status (cm) | 0.163 | |||
| ≥2 | 25 | 9.02 ± 2.08 | 1.424 | |
| < 2 | 12 | 7.97 ± 2.17 | ||
| Triple Negative Breast Cancer (TNBC, n) | 0.206 | |||
| Yes | 7 | 9.61 ± 1.83 | 1.288 | |
| No | 30 | 8.46 ± 2.17 | ||
| Her-2 Positive | 0.857 | |||
| Yes | 11 | 8.78 ± 2.55 | 0.181 | |
| No | 26 | 8.64 ± 1.99 | ||
| estrogen receptor (ER, n) | 0.026* | |||
| Positive | 27 | 8.21 ± 2.14 | −2.318 | |
| Negative | 10 | 9.94 ± 1.61 | ||
| progesterone receptor (PR, n) | 0.311 | |||
| Positive | 23 | 8.40 ± 2.12 | −1.027 | |
| Negative | 14 | 9.14 ± 2.16 | ||
| Androgen Receptor (AR, n) | 0.018* | |||
| Positive | 30 | 8.34 ± 2.15 | −2.687 | |
| Negative | 7 | 10.13 ± 1.43 | ||
| Tumor metastasis status | 0.922 | 0.363 | ||
| Yes | 8 | 9.30 ± 1.91 | ||
| No | 29 | 8.51 ± 2.20 | ||
| TNM stage | 0.639 | 0.595 | ||
| I | 11 | 9.11 ± 1.93 | ||
| II | 24 | 8.37 ± 2.26 | ||
| III | 2 | 9.93 ± 1.53 | ||
| IV | 0 | NA | ||
| Edmondson grading | −0.846 | 0.404 | ||
| early stages (I–II) | 35 | 8.61 ± 2.16 | ||
| advanced stages (III–IV) | 2 | 9.93 ± 1.53 |
Abbreviations: TNM, Tumor Node Metastasis; HER-2, human epidermal growth factor receptor-2; CEA, carcino-embryonic antigen; CA15-3, carbohydrate antigen 15-3; NA, NOT applicable.
*P < 0.05.
*P < 0.01.